TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05083637
Drug: L- carnitine oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
Study: NCT05010460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally 100mg every other day for 5-8 days prior to CABG
Study: NCT05366231
Drug: Kesuting syrup
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully.
Study: NCT05366231
Drug: LianHuaQingWen Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully.
Study: NCT00415935
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04773405
Drug: a 1: 1 mixture of 2% lidocaine with 5ug/ml epinephrine and 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELAV90) of cases of the aforementioned local anaesthetic (LA) mixture, in order to produce the surgical anaesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries. Based on the principal investigator's clinical experience, the initial volume of 21ml will be used. Depending on the success or failure of the SeTB, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 3ml (1ml for each trunk of brachial plexus located above the clavicle). The upper dose limit of the study to minimize the potential for local anaesthetic systemic toxicity will be 30ml and the lower dose limit will be 12ml, which will be of no clinical importance.
Study: NCT05068284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion; Subcutaneous Injection
Study: NCT05068284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT04773600
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream for topical application
Study: NCT05621252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06054984
Drug: TCR-T Cells Injection（GB3010 Cells Injection）
Approvals — FDA: no, EMA: no, PMDA: no
Description: The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced to express a T-cell Receptor that recognizes the RAS/TP53.Patients were sequentially enrolled into 3 dose escalation groups(dose level 1-3) :5×10\^8±20%,5×10\^9±20%,5×10\^10±20%.
Study: NCT05633420
Drug: Pyramax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant body weight~* ≥65 kg (Pyramax 4 tablets)~* ≥45 kg and \<65 kg (Pyramax 3 tablets)
Study: NCT06501638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take placebo for intervention First week, half the tablet, p.o., bid. Second to Sixth week, one tablet, p.o., bid
Study: NCT03864094
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,1 microg/kg
Study: NCT03864094
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,7 microg/kg
Study: NCT05809180
Drug: Pro-miniCHOP-like regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
Study: NCT06245330
Drug: AST-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid formulation for Intravenous infusion
Study: NCT05809180
Drug: R-miniCHOP-like regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
Study: NCT06372223
Drug: SPH5030
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH5030 tablets：400mg,orally, Dosing in the fasted state followed by fed dosing.
Study: NCT06372223
Drug: SPH5030
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH5030 tablets：400mg, orally, Dosing in the fed state followed by fasted dosing.
Study: NCT05732454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
Study: NCT03954483
Drug: Buspirone 10 Mg Oral Tablet
Normalized name: busPIRone 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered prior to experiments.
Study: NCT03954483
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered prior to experiments.
Study: NCT03249844
Drug: Methylprednisolone + prednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~* week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~* week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),
Study: NCT04947761
Drug: modified Tian Wang Bu Xin Dan hydrogel patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
Study: NCT04755946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05369039
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic corticosteroid
Study: NCT06150560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
Study: NCT05212987
Drug: FCN-098
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.
Study: NCT05155254
Drug: IO102-IO103
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously
Study: NCT04583280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant of age group 1, 2, 3 and 4 will receive matching placebo of rilematovir BID from Days 1 to Day 7 or Day 8 as per assigned age group.
Study: NCT05731596
Drug: Rosuvastatin 20 Mg Oral Tablet
Normalized name: rosuvastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg will be administered orally once daily for 3 Months
Study: NCT05731596
Drug: Coenzyme Q10 100 MG Oral Capsule
Normalized name: Coenzyme Q10 100 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q10 100 mg will be administered orally once daily for 3 Months
Study: NCT06126315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05278182
Drug: Naoxintong Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with acute myocardial infarct on the basis of optimal medical therapy will take Naoxintong capsules following directions for 12 months
Study: NCT05278182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with acute myocardial infarct on the basis of optimal medical therapy will take placebo following directions for 12 months
Study: NCT04661540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
Study: NCT05241106
Drug: HYML-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
Study: NCT05048160
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
Study: NCT05125276
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin
Study: NCT05491785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol placebo tablets
Study: NCT06236178
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of 40 mg methylprednisolone acetate
Study: NCT06236178
Drug: Autologous Blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of autologous venous blood
Study: NCT06236178
Drug: Local Anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of 2% prilocaine HCl
Study: NCT06248086
Drug: ASP2802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT06800313
Drug: HLD-0915
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Study: NCT06135350
Drug: Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:~* 2400 mg/day (4 tablets twice a day) for the first 2 days and;~* 1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days.
Study: NCT05642949
Drug: MHB036C
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).
Study: NCT04619862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm descriptions
Study: NCT06128252
Drug: XELOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin + capecitabine
Study: NCT06337032
Drug: F/TAF (High Dose Tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/25 mg fixed-dose combination (FDC) tablet administered orally
Study: NCT06337032
Drug: F/TAF (Low Dose Tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/10 mg FDC tablet administered orally
Study: NCT06337032
Drug: F/TAF (Lowest Dose Tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120/15 mg FDC tablet administered orally
Study: NCT06337032
Drug: F/TAF (High Dose TOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60/7.5 mg tablet for oral suspension (TOS) administered orally
Study: NCT06337032
Drug: F/TAF (Low Dose TOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30/3.75 mg TOS administered orally
Study: NCT06337032
Drug: F/TAF (Lowest Dose TOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15/1.88 mg TOS administered orally
Study: NCT06337032
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg tablet administered orally
Study: NCT06337032
Drug: E/C/F/TAF (Low Dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/90/120/6 mg tablet administered orally
Study: NCT06337032
Drug: B/F/TAF (High Dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg FDC tablet administered orally
Study: NCT06337032
Drug: B/F/TAF (Lowest Dose TOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.76/15/1.88 mg TOS administered orally
Study: NCT06337032
Drug: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)
Study: NCT06337032
Drug: DRV
Normalized name: Urinal Male Drv RTLPC23201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to the prescribing information
Study: NCT06212583
Drug: Androgen deprivation therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All ADT is provided as best prescribed for patient per their medical oncologist.
Study: NCT04069052
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.
Study: NCT04069052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room air (placebo) flowed into a mask and breathed in.
Study: NCT04944953
Drug: Botulinum toxin type A injection [HG-102]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration, Day 0, 20 units
Study: NCT06212076
Drug: IPG1094
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg
Study: NCT05291234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT06672978
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as prescribed by the study physician in accordance with the local marketing authorizations
Study: NCT05203692
Drug: DS-7011a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous or subcutaneous administration, single dose
Study: NCT05203692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous or subcutaneous administration, single dose
Study: NCT05002140
Drug: XRD-0394
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose
Study: NCT04914546
Drug: LY3819469
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04914546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05633147
Drug: Drug drug interaction (DDI) - Clarithromycin (Part I)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
Study: NCT06496997
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone at an equivalent dose of 350 mg/day
Study: NCT05698407
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
Study: NCT04757337
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 x 3-week cycles corresponding to a maximal duration of 18 weeks
Study: NCT04757337
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Until progression up to 24 months
Study: NCT04673864
Drug: D012, D326, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT04786600
Drug: pre-specified sequence of FDA-approved drugs and drug combinations
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
Study: NCT04676737
Drug: TTHX1114(NM141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTHX1114
Study: NCT05753956
Drug: 5 Methoxy N,N Dimethyltryptamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH002 administered via i.v. bolus injection(s)
Study: NCT05753956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH002 placebo administered via i.v. bolus injection
Study: NCT06114979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive placebo tablet.
Study: NCT06767969
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophenl 500mg (500mg/50ml) was infused intravenously every 6 hours( a single infusion is completed within 15-30 minutes) from the beginning of endovascular treatment to 48 hours after treatment.
Study: NCT06589245
Drug: Alvesco Inhalant Product
Normalized name: Alvesco Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Alvesco will be administered daily for 14 days at escalating doses of 80mcg and 160mcg.
Study: NCT06769204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs of saline into the cervix and cervical canal 5 minutes before the procedure
Study: NCT06588153
Drug: Prolia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection in pre-filled syringe.
Study: NCT06798636
Drug: Placebo with cognitive behavioural therapy intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an oral placebo comparator preceding a mental imagery rescripting procedure
Study: NCT04792723
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synco (HK) oral aspirin 80mg tablet
Study: NCT05702762
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/kg intramuscular injection
Study: NCT05702762
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral antibiotic multi-day dosing based on local antibiogram
Study: NCT05199324
Drug: Standard of care intravenous antibiotics (e.g. ceftriaxone, cefazolin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the standard arm will continue to receive an active intravenous antibiotic therapy for at least another 24 hours post-randomisation before clinical re-assessment and decision making by the treating doctor
Study: NCT06542237
Drug: YCT-529
Normalized name: YCT-529
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Phase 1b part of the study, 4 dosing cohorts and one optional 5th cohort with 4 participants will be evaluated (up to 20 participants): 15, 45, 90 and 180 mg. In the Phase 2a part, up to 3 cohorts of up to 10 participants (up to 30 participants) will receive doses within the range of doses that was well tolerated and had biological activity in the Phase 1b portion.
Study: NCT06627556
Drug: H021 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: H021 placebo oral tablet.
Study: NCT05762458
Drug: Ammoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ammoxetine hydrochloride enteric-coated tablets
Study: NCT05762458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to Ammoxetine.
Study: NCT05991362
Drug: GFH312 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive single dose of GFH312 100 mg orally
Study: NCT05991362
Drug: GFH312 120mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days
Study: NCT05918692
Drug: BMF-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product
Study: NCT06112262
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison between heparin and hirudin
Study: NCT04718051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.
Study: NCT05647954
Drug: HX008 + TACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX008 Subjects receive HX008 200 mg intravenous (IV) ,day1,every 3 weeks (Q3W) Procedure: TACE cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions).
Study: NCT05535920
Drug: LOKELMA 5 GM Powder for Oral Suspension
Normalized name: Lokelma 5 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will use Lokelma supplementation on off-dialysis days (4 days/week) while receiving hemodialysis with 3.0 K+/2.5 Ca++ mEq dialysate bath. The individual starting dose will be 5.0 grams, and may be titrated weekly in 5.0 gram increments up to 15.0 grams to maintain K+ between 4.0 and 5.5 mEq/L.
Study: NCT05035953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone Dexborneol matching injection, addition to thrombolysis
Study: NCT05065398
Drug: HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450mg bid, take orally
Study: NCT06348576
Drug: AD-209 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT06348576
Drug: AD-2091 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks